Clinical profile and treatment outcomes of drug-resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program

Lung India

Volumn 30, Issue 4, 2013, Pages 316-320

  Dholakia, Yatin N ^a   Shah, Divya P ^b  

^a LARSEN AND TOUBRO LIMITED   (India)

^b Mumbai Municipal Corporation   (India)

Author keywords

Amplification of resistance; daily directly observed treatment strategy; individualized treatment; scaling up DST for second line drugs

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; CLINICAL ARTICLE; DIABETIC PATIENT; DRUG RESISTANT TUBERCULOSIS; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GOITER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; INDIA; LUNG TUBERCULOSIS; MALE; MENTAL DISEASE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM; NONHUMAN; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; RETROSPECTIVE STUDY; SCALE UP; SHORT COURSE THERAPY; TENDINITIS; TUBERCULOUS LYMPHADENITIS; TUBERCULOUS OSTEOMYELITIS;

EID: 84889665337     PISSN: 09702113     EISSN: 0974598X     Source Type: Journal    
DOI: 10.4103/0970-2113.120608     Document Type: Article

References (25)

1. TB India 2011 Revised National TB Control Program Annual Status Report. Available from: Http://www.tbcindia.nic.in/pdfs/RNTCP%20 TB%20India%202011.pdf. Last accessed 20.06.2013
2. D'souza DT, Mistry NF, Vira TS, Dholakia Y, Hoffner S, Pasvol G, et al. High levels of multidrug resistant tuberculosis in new and treatmentfailure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India. BMC Public Health 2009;9:211
3. Dholakia Y, D'souza DT, Tolani MP, Chatterjee A, Mistry NF. Chest X-rays and associated clinical parameters in pulmonary tuberculosis cases from the National Tuberculosis Program, Mumbai, India. Infect Dis Rep 2012;4:e10
4. Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India 2012. Available from: Http://www.tbcindia.nic.in/pdfs/ Guidelines%20for%20PMDT%20in%20India%20%20May%202012. pdf. Last accessed 20.06.2013
5. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug resistant tuberculosis bacilli: Super extensively drug-resistant tuberculosis or totally drug resistant strains in Iran. Chest 2009;136:420-5
6. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally Drug resistant tuberculosis in India. Clin Infect Dis 2012;54:579-81
7. Chadha SS, Sharath BN, Reddy K, Jaju J, Vishnu PH, Rao S, et al. Operational challenges in diagnosing multi-Drug resistant TB and initiating treatment in Andhra Pradesh, India. PLoS One 2011;6:e26659
8. Thomson RM. Changing epidemiology of pulmonary nontuberculous mycobacterial infections. Emerg Infect Dis 2010;16:1576-83
9. Mistry NF, Dholakia Y, D'Souza DT, Taylor M, Hoffner S, Birdi TJ. Rhodococcus and Mycobacterium tuberculosis: Masquerade or mixed infection. Int J Tuberc Lung Dis 2006;10:351-3
10. Van Deun A, Rieder HL. DOT, S, or DOTS? PHA 2012; 2(1):3-4
11. Chang KC, Leung CC, Grosset J, Yew WW. Treatment of tuberculosis and optimal dosing schedules. Thorax 2011;66:997-1007
12. Dholakia YN. Treatment results among category 2 cases. Indian J Tuberc 2000;47:188
13. Udwadia ZF. Totally drug-resistant tuberculosis in India: Who let the djinn out? Respirology 2012;17:741-2
14. Treatment of Tuberculosis Guidelines. 4th ed. WHO/HTM/TB/2009.420
15. Althomsons SP, Cegielski JP. Impact of second-line drug resistance on tuberculosis treatment outcomes in the United States: MDR-TB is bad enough. Int J Tuberc Lung Dis 2012;16:1331-4
16. Resch SC, Salomon JA, Murray M, Weinstein MC. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 2006;3:e241
17. Dholakia YN. Ethics, human rights and programmatic management of drug-resistant tuberculosis. Lung India 2012;29:95-6
18. Isaakidis P, Varghese B, Mansoor H, Cox HS, Ladomirska J, Saranchuk P, et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One 2012;7:e40781
19. Liu CH, Li L, Chen Z, Wang Q, Hu YL, Zhu B, et al. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: A 13-year experience. PLoS One 2011;6:e19399
20. Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S, Chen MP, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 2010;36:584-93
21. Malla P, Kanitz EE, Akhtar M, Falzon D, Feldmann K, Gunneberg C, et al. Ambulatory-Based Standardized Therapy for Multi-Drug Resistant Tuberculosis: Experience from Nepal, 2005-2006. PLoS One 2009;4:e8313
22. Joseph P, Desai VB, Mohan NS, Fredrick JS, Ramachandran R, Raman B, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res 2011;133:529-34
23. Isaakidis P, Cox HS, Varghese B, Montaldo C, Da Silva E, Mansoor H, et al. Ambulatory multi-Drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PLoS One 2011;6:e28066
24. Sarin R, Singla R, Visalakshi P, Jaiswal A, Puri MM, Khalid UK, et al. Smear microscopy as surrogate for culture during follow up of pulmonary MDR TB patients on DOTS plus treatment. Indian J Tuberc 2010;57: 134-40
25. Kurbatova EV, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, et al. Frequency and type of microbiological monitoring of multidrugresistant tuberculosis treatment. Int J Tuberc Lung Dis 2011;15:1553-5